PhRMA Drug Pricing Comments Mainly Stick To Script
Executive Summary
With only one new proposal, brand industry association seems to banking on strength of past policy positions as Trump's drug pricing blueprint moves towards implementation stage.
You may also be interested in...
FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs
FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.
Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price
Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.
Congressional Action On Drug Pricing Blueprint Likely To Be Modest
Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.